

## **Communiqué from Bio-Works Technologies' annual general meeting 2023**

**Bio-Works Technologies' annual general meeting was held 26 May 2023. The following resolutions were made at the annual general meeting, among other resolutions.**

The meeting adopted the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2022.

The meeting resolved that no dividend shall be paid for the financial year 2022.

The meeting granted the board members and CEO discharge from liability for the financial year 2022.

The meeting resolved that the number of board members shall be four and re-elected Peter von Ehrenheim, Kirsti Gjellan, Peter Nählstedt and Johan Sedihn. Peter von Ehrenheim was re-elected as chairman of the board. The meeting resolved that directors' fees of SEK 260,000 shall be paid to the chairman of the board and SEK 130,000 to each of the other directors not employed by the company. In addition to director fees', no fees shall be paid for work in the board's committees.

Öhrlings PricewaterhouseCoopers AB was re-elected as auditor. Leonard Daun will continue as the auditor in charge. The auditor's fee shall be paid in accordance with approved account.

In accordance with the board's proposal, the meeting resolved to introduce a long-term warrant-based incentive program, for senior executives and key employees. The meeting resolved on an issue of a maximum of 200,000 warrants for this purpose. The warrants are issued at a price corresponding to the warrants' market value at the time of subscription calculated according to the Black & Scholes' model. The subscription price per share shall correspond to 125 percent of the volume-weighted average price paid for the company's share during a period of time after the meeting. Each warrant entitles the holder to subscribe for one new share in the company during the period 1 June 2026 – 30 June 2026. If all warrants are utilized for subscription, 200,000 new shares may be issued, corresponding to a dilution of approximately 0.57 percent of the total number of shares and votes in the company. The purpose of the program is, i.a., to encourage shareholding among senior executives and key employees, to increase their motivation to achieve or exceed the company's financial targets and to retain and recruit important people.

The meeting also resolved, in accordance with the board's proposal, to insert a new paragraph in the articles of association to enable the board to collect power of attorneys and to allow postal voting prior to annual general meetings.

The meeting resolved, in accordance with the board's proposal, to authorize the board for the period until the next annual general meeting, on one or more occasions, with or without preferential rights for shareholders, to decide on issue of new shares. The authorization includes shares corresponding to a maximum of ten (10) percent of the total number of issued shares in the Company at the time when the board first utilizes the authorization. The purpose of the authorization is to increase the company's financial flexibility and the board's margin for manoeuvre. If the board decides to issue shares with deviation from the shareholders' preferential rights, the reason shall be to broaden the owner circle, raise working capital, acquire companies or businesses or to acquire capital for such acquisitions.

The annual general meeting minutes, including complete resolutions, will shortly be published on the company's website.

**Contacts**

For more information, please visit the Bio-Works homepage at, [www.bio-works.com](http://www.bio-works.com) or contact: Jonathan Royce, CEO, e-mail: [jonathan.royce@bio-works.com](mailto:jonathan.royce@bio-works.com), phone: +46 70 1434143.

**About Bio-Works**

Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works' next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North ("BIOWKS"), and FNCA Sweden AB, +46 (0) 8-528 00 399, [info@fnca.se](mailto:info@fnca.se), is appointed Certified Adviser. For more information, [www.bio-works.com](http://www.bio-works.com).

**Attachments**

[Communiqué from Bio-Works Technologies' annual general meeting 2023](#)